# Efficacy of Everolimus-containing Chemotherapy in HER2- mBC Patients With PI3K/AKT/mTOR Mutations Study

> **NCT05054166** · — · COMPLETED · sponsor: **Zhejiang Cancer Hospital** · enrollment: 14 (actual)

## Conditions studied

- Breast Cancer
- PI3K/AKT/mTOR Pathway Mutation
- Everolimus

## Interventions

- **OTHER:** No intervention, it was a retrospective study.

## Key facts

- **NCT ID:** NCT05054166
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-01
- **Primary completion:** 2021-08-01
- **Final completion:** 2021-08-30
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2021-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05054166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05054166, "Efficacy of Everolimus-containing Chemotherapy in HER2- mBC Patients With PI3K/AKT/mTOR Mutations Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05054166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*